PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31992334-9	2020	Furthermore, CD44-positive HCC PDOs were obviously resistant to sorafenib, and sorafenib increased CD44 levels.	Sorafenib	64-73	CD44 molecule (Indian blood group)	Homo sapiens	13-17	
33199679-8	2020	More importantly, the treatment of HCC cells expressing CD44 (the main PRG4 receptor) with rhPRG4 dramatically enhances the growth-limiting capacity of sorafenib and regorafenib, whereas not significantly affecting cell proliferation per se.	Sorafenib	152-161	CD44 molecule (Indian blood group)	Homo sapiens	56-60	
31992334-9	2020	Furthermore, CD44-positive HCC PDOs were obviously resistant to sorafenib, and sorafenib increased CD44 levels.	Sorafenib	79-88	CD44 molecule (Indian blood group)	Homo sapiens	99-103	
31992334-11	2020	In addition, there was a highly synergistic effect in vitro and in vivo on the suppression of cell viability and malignant properties when sorafenib and GANT61 were added to CD44-positive HCC PDOs and cell lines, respectively.	Sorafenib	139-148	CD44 molecule (Indian blood group)	Homo sapiens	174-178	
31992334-12	2020	Furthermore, the upregulation of CD44 and Hedgehog signaling induced by sorafenib was reversed by GANT61.	Sorafenib	72-81	CD44 molecule (Indian blood group)	Homo sapiens	33-37	
31992334-13	2020	CONCLUSIONS: GANT61 significantly suppressed Hedgehog signaling to reverse sorafenib resistance in CD44-positive HCC.	Sorafenib	75-84	CD44 molecule (Indian blood group)	Homo sapiens	99-103	
31992334-14	2020	The combination of sorafenib and Hedgehog signaling inhibitors might be effective in HCC patients with high CD44 levels as a personalized-medicine approach.	Sorafenib	19-28	CD44 molecule (Indian blood group)	Homo sapiens	108-112	
31992334-9	2020	Furthermore, CD44-positive HCC PDOs were obviously resistant to sorafenib, and sorafenib increased CD44 levels.	Sorafenib	79-88	CD44 molecule (Indian blood group)	Homo sapiens	13-17	
28627617-0	2017	Sorafenib controls the epithelial-mesenchymal transition of ovarian cancer cells via EGF and the CD44-HA signaling pathway in a cell type-dependent manner.	Sorafenib	0-9	CD44 molecule (Indian blood group)	Homo sapiens	97-101	
29899840-5	2018	CD44 was significantly increased in Huh7 cells made resistant to sorafenib.	Sorafenib	65-74	CD44 molecule (Indian blood group)	Homo sapiens	0-4	
29899840-10	2018	Moreover, a combination of INK128 and sorafenib showed improved anti-proliferative effects in CD44high HCC cells.	Sorafenib	38-47	CD44 molecule (Indian blood group)	Homo sapiens	94-98	
29899840-12	2018	Since the clinical response to sorafenib is highly variable, our findings suggest that ATP-competitive mTOR inhibitors may be effective in treating advanced, CD44-expressing HCC patients who are insensitive to sorafenib.	Sorafenib	31-40	CD44 molecule (Indian blood group)	Homo sapiens	158-162	
25053293-8	2015	Targeted CD44 knock-down in the mesenchymal-like cells indicated that CD44 plays an active role in protecting HCC cells from sorafenib-induced apoptosis.	Sorafenib	125-134	CD44 molecule (Indian blood group)	Homo sapiens	9-13	
25053293-8	2015	Targeted CD44 knock-down in the mesenchymal-like cells indicated that CD44 plays an active role in protecting HCC cells from sorafenib-induced apoptosis.	Sorafenib	125-134	CD44 molecule (Indian blood group)	Homo sapiens	70-74	
25053293-10	2015	In conclusion, a mesenchymal profile and expression of CD44, linked to activation of the TGF-beta pathway, may predict lack of response to sorafenib in HCC patients.	Sorafenib	139-148	CD44 molecule (Indian blood group)	Homo sapiens	55-59	
23228386-13	2013	Hymecromone plus sorafenib up-regulated pro-apoptotic indicators and down-regulated Mcl-1, CD44, RHAMM, phospho-epidermal growth factor receptor and phospho-cMet.	Sorafenib	17-26	CD44 molecule (Indian blood group)	Homo sapiens	91-95	
23314174-6	2013	Notably, the combination of sorafenib and radiation eliminated CD44+CD24-/low             cells preferentially, which highly expressed hypoxia-inducible factor (HIF)-1alpha             and effectively inhibited primary and secondary mammosphere formation in MDA-MB-231             cells.	Sorafenib	28-37	CD44 molecule (Indian blood group)	Homo sapiens	63-67	
27461522-6	2016	Sorafenib diminished the self-renewal capacity and downregulated the expression of stem cell biomarkers (CD133, CD44 and ALDH1) in a dose-dependent manner, while BrMC cooperated with sorafenib to strengthen this inhibition.	Sorafenib	0-9	CD44 molecule (Indian blood group)	Homo sapiens	112-116